A review of 28 studies has found that the proportion of smokers appear to be lower than non-smokers among hospitalised COVID-19 patients, reported Hindustan Times.
The research by academics from University College London and Royal Veterinary College, London included 22 studies conducted in China, three in the United States, one in South Korea, one in France and one across multiple international sites with data predominantly collected in the United Kingdom.
The UK study showed that the proportion of smokers among COVID-19 patients was just 5 per cent, a third of the national rate of 14.4 per cent.
Similarly, the French study found that the rate of smokers was four times lower. In China, a study revealed that just 3.8 per cent of patients were smokers compared to more than half of the population who regularly smoke cigarettes.
The two studies in the review showed that when smokers test positive for the virus, the complications are likely to become so serious that they require ventilation support.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
“Across 28 observational studies, there is substantial uncertainty arising from the recording of smoking status on whether current and/or former smoking status is associated with SARS-CoV-2 infection, hospitalisation or mortality,” concluded the “pre-print” paper published on the study-sharing website Qeios.
“There is low-quality evidence that current and former smoking compared with never is associated with greater disease severity in those hospitalised for COVID-19,” wrote authors Lion Shahab, Jamie Brown and Olga Perski of UCL and David Simons of Royal Veterinary College.
The researchers said the majority of the 28 studies reported current and/or former smoking status but had high levels of missing data and/or did not explicitly state whether the remaining participants were never smokers.